Compliance of Clinical Microbiology Laboratories in the United States with Current Recommendations for Processing Respiratory Tract Specimens from Patients with Cystic Fibrosis

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2006 Apr 7

PMID 16597890

Citations 11

Authors

Juyan Zhou

Elizabeth Garber

Manisha Desai

Lisa Saiman

Affiliations

Soon will be listed here.

Abstract

Respiratory tract specimens from patients with cystic fibrosis (CF) require unique processing by clinical microbiology laboratories to ensure detection of all potential pathogens. The present study sought to determine the compliance of microbiology laboratories in the United States with recently published recommendations for CF respiratory specimens. Microbiology laboratory protocols from 150 of 190 (79%) CF care sites were reviewed. Most described the use of selective media for Burkholderia cepacia complex (99%), Staphylococcus aureus (82%), and Haemophilus influenzae (89%) and identified the species of all gram-negative bacilli (87%). Only 52% delineated the use of agar diffusion assays for susceptibility testing of Pseudomonas aeruginosa. Standardizing laboratory practices will improve treatment, infection control, and our understanding of the changing epidemiology of CF microbiology.

Citing Articles

Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis.

Schwarz C, Bouchara J, Buzina W, Chrenkova V, Dmenska H, de la Pedrosa E Mycopathologia. 2017; 183(1):7-19.

PMID: 29098487 PMC: 7089279. DOI: 10.1007/s11046-017-0205-x.

Sputum DNA sequencing in cystic fibrosis: non-invasive access to the lung microbiome and to pathogen details.

Feigelman R, Kahlert C, Baty F, Rassouli F, Kleiner R, Kohler P Microbiome. 2017; 5(1):20.

PMID: 28187782 PMC: 5303297. DOI: 10.1186/s40168-017-0234-1.

Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices.

de Dios Caballero J, Del Campo R, Tato M, Gomez G de la Pedrosa E, Cobo M, Lopez-Causape C BMC Microbiol. 2015; 14:335.

PMID: 25927861 PMC: 4302700. DOI: 10.1186/s12866-014-0335-y.

A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic Fibrosis.

Lucarelli M, Bruno S, Pierandrei S, Ferraguti G, Stamato A, Narzi F Mol Med. 2015; 21:257-75.

PMID: 25910067 PMC: 4503653. DOI: 10.2119/molmed.2014.00229.

European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre.

Conway S, Balfour-Lynn I, De Rijcke K, Drevinek P, Foweraker J, Havermans T J Cyst Fibros. 2014; 13 Suppl 1:S3-22.

PMID: 24856776 PMC: 7105239. DOI: 10.1016/j.jcf.2014.03.009.

References

Garner J . Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1996; 17(1):53-80. DOI: 10.1086/647190. View

. Microbiological processing of respiratory specimens from patients with cystic fibrosis. Can J Infect Dis. 2012; 4(3):166-9. PMC: 3250786. DOI: 10.1155/1993/989086. View

Wong K, Roberts M, Owens L, Fife M, Smith A . Selective media for the quantitation of bacteria in cystic fibrosis sputum. J Med Microbiol. 1984; 17(2):113-9. DOI: 10.1099/00222615-17-2-113. View

van Pelt C, Verduin C, Goessens W, Vos M, Tummler B, Segonds C . Identification of Burkholderia spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods. J Clin Microbiol. 1999; 37(7):2158-64. PMC: 85108. DOI: 10.1128/JCM.37.7.2158-2164.1999. View

LiPuma J . Burkholderia cepacia epidemiology and pathogenesis: implications for infection control. Curr Opin Pulm Med. 2000; 4(6):337-41. DOI: 10.1097/00063198-199811000-00005. View

Burns J, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D . Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis. 2001; 39(4):257-60. DOI: 10.1016/s0732-8893(01)00234-6. View

Saiman L, Burns J, Larone D, Chen Y, Garber E, Whittier S . Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 2003; 41(1):492-4. PMC: 149561. DOI: 10.1128/JCM.41.1.492-494.2003. View

Miller M, Gilligan P . Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol. 2003; 41(9):4009-15. PMC: 193835. DOI: 10.1128/JCM.41.9.4009-4015.2003. View

Henry D, CAMPBELL M, LiPuma J, Speert D . Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol. 1997; 35(3):614-9. PMC: 229637. DOI: 10.1128/jcm.35.3.614-619.1997. View

10.

Saiman L, Burns J, Whittier S, Krzewinski J, Marshall S, Jones R . Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol. 1999; 37(9):2987-91. PMC: 85429. DOI: 10.1128/JCM.37.9.2987-2991.1999. View

11.

Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z . Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol. 2001; 39(11):3942-5. PMC: 88468. DOI: 10.1128/JCM.39.11.3942-3945.2001. View

12.

McMenamin J, Zaccone T, Coenye T, Vandamme P, LiPuma J . Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest. 2000; 117(6):1661-5. DOI: 10.1378/chest.117.6.1661. View

13.

Kiska D, Kerr A, Jones M, Caracciolo J, Eskridge B, Jordan M . Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol. 1996; 34(4):886-91. PMC: 228911. DOI: 10.1128/jcm.34.4.886-891.1996. View

14.

Carson L, Tablan O, Cusick L, Jarvis W, Favero M, Bland L . Comparative evaluation of selective media for isolation of Pseudomonas cepacia from cystic fibrosis patients and environmental sources. J Clin Microbiol. 1988; 26(10):2096-100. PMC: 266823. DOI: 10.1128/jcm.26.10.2096-2100.1988. View

15.

Shelly D, Spilker T, Gracely E, Coenye T, Vandamme P, LiPuma J . Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture. J Clin Microbiol. 2000; 38(8):3112-5. PMC: 87204. DOI: 10.1128/JCM.38.8.3112-3115.2000. View

16.

Gilligan P, Gage P, Bradshaw L, Schidlow D, DECICCO B . Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol. 1985; 22(1):5-8. PMC: 268309. DOI: 10.1128/jcm.22.1.5-8.1985. View

17.

LiPuma J . Burkholderia cepacia. Management issues and new insights. Clin Chest Med. 1998; 19(3):473-86, vi. DOI: 10.1016/s0272-5231(05)70094-0. View

18.

Burns J, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z . Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 2000; 38(5):1818-22. PMC: 86597. DOI: 10.1128/JCM.38.5.1818-1822.2000. View

19.

Welch D, Muszynski M, PAI C, Marcon M, Hribar M, Gilligan P . Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis. J Clin Microbiol. 1987; 25(9):1730-4. PMC: 269317. DOI: 10.1128/jcm.25.9.1730-1734.1987. View

20.

Shreve M, Butler S, Kaplowitz H, Rabin H, Stokes D, Light M . Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol. 1999; 37(3):753-7. PMC: 84543. DOI: 10.1128/JCM.37.3.753-757.1999. View